Mp Biomedicals
Mp Biomedicals, a leading name in the life sciences and biotechnology sector, is headquartered in New Zealand. Founded in 1997, the company has established a strong presence in key operational regions, including North America and Europe. Specialising in the development and manufacturing of high-quality research reagents, laboratory equipment, and diagnostic tools, Mp Biomedicals is renowned for its innovative solutions that cater to the needs of researchers and healthcare professionals. With a diverse product portfolio that includes molecular biology reagents, protein purification kits, and custom antibody services, Mp Biomedicals stands out for its commitment to quality
DitchCarbon Score
How does Mp Biomedicals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mp Biomedicals's score of 6 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Mp Biomedicals's reported carbon emissions
MP Biomedicals, headquartered in New Zealand, currently does not report any specific carbon emissions data for the latest year. However, the company is committed to reducing its carbon footprint and has established near-term climate targets. As of July 2023, MP Biomedicals is classified as "Committed" to near-term reduction targets, although no specific numerical targets have been disclosed. The company operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector, which is increasingly under pressure to address climate change. While MP Biomedicals has not committed to a net-zero target, it is actively engaging in initiatives aimed at reducing its emissions, reflecting a growing trend in the industry towards sustainability and environmental responsibility. In summary, while specific emissions data is unavailable, MP Biomedicals is taking steps to align with climate commitments, demonstrating a proactive approach to environmental stewardship in the pharmaceutical sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mp Biomedicals is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
